References
1. Tringale KR, Marshall D, Mackey TK, Connor M, Murphy JD,
Hattangadi-Gluth JA. Types and Distribution of Payments From Industry to
Physicians in 2015. JAMA. 2017;317(17):1774-84.
2. Marshall DC, Jackson ME, Hattangadi-Gluth JA. Disclosure of Industry
Payments to Physicians: An Epidemiologic Analysis of Early Data From the
Open Payments Program. Mayo Clin Proc. 2016;91(1):84-96.
3. Ahlawat A, Narayanaswami P. Financial relationships between
neurologists and industry: The 2015 Open Payments database. Neurology.
2019;92(21):1006-13.
4. Inoue K, Figueroa JF, DeJong C, Tsugawa Y, Orav EJ, Shen C, Kazi DS.
Association Between Industry Marketing Payments and Prescriptions for
PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors in the
United States. Circulation: Cardiovascular Quality and Outcomes.
2021;14(5):e007521.
5. Murayama A. Industry-sponsored meal payments are associated with
prescriptions and Medicare expenditures on brand-name colchicine in the
United States. International Journal of Rheumatic Diseases.
2023;n/a(n/a).
6. Murayama A. Pharmaceutical industry-sponsored meals and prescriptions
of biologics for asthma. J Allergy Clin Immunol Pract.
2023;11(9):2916-8.
7. Murayama A, Kida F, Ozaki A, Saito H, Sawano T, Tanimoto T. Financial
and Intellectual Conflicts of Interest Among Japanese Clinical Practice
Guidelines Authors for Allergic Rhinitis. Otolaryngol Head Neck Surg.
2022;166(5):869-76.
8. Murayama A, Yamada K, Yoshida M, Kaneda Y, Saito H, Sawano T, et al.
Evaluation of Conflicts of Interest among Participants of the Japanese
Nephrology Clinical Practice Guideline. Clin J Am Soc Nephrol.
2022;17(6):819-26.
9. Nejstgaard CH, Bero L, Hrobjartsson A, Jorgensen AW, Jorgensen KJ, Le
M, Lundh A. Association between conflicts of interest and favourable
recommendations in clinical guidelines, advisory committee reports,
opinion pieces, and narrative reviews: systematic review. BMJ.
2020;371:m4234.
10. Steinbrook R. Guidance for guidelines. N Engl J Med.
2007;356(4):331-3.
11. Anderson TS, Krieger MS, Marshall BDL, Cerdá M, Hadland S. Financial
Payments to Teaching Hospitals by Companies Marketing Opioids. J Gen
Intern Med. 2020;35(10):3108-10.
12. Sawano T, Ozaki A, Saito H, Shimada Y, Tanimoto T. Payments From
Pharmaceutical Companies to Authors Involved in the Valsartan Scandal in
Japan. JAMA Netw Open. 2019;2(5):e193817.
13. Murata N, Ozaki A, Murayama A, Sawano T, Tanimoto T. The Diovan
scandal in Japan; don’t let bygones be bygones. J Hum Hypertens.
2022;36(5):500-1.
14. Ozaki A, Saito H, Senoo Y, Sawano T, Shimada Y, Kobashi Y, et al.
Overview and transparency of non-research payments to healthcare
organizations and healthcare professionals from pharmaceutical companies
in Japan: Analysis of payment data in 2016. Health Policy.
2020;124(7):727-35.
15. Murayama A, Shigeta H, Kamamoto S, Yamashita E, Saito H, Sawano T,
et al. Pharmaceutical Payments to Japanese Board-Certified Head and Neck
Surgeons Between 2016 and 2019. OTO Open. 2023;7(1):e31.
16. Murayama A, Kamamoto S, Saito H, Yamada K, Bhandari D, Shoji I, et
al. Pharmaceutical Payments to Japanese Board-Certified Infectious
Disease Specialists: A Four-Year Retrospective Analysis of Payments from
92 Pharmaceutical Companies between 2016 and 2019. Int J Environ Res
Public Health. 2022;19(12):7417.
17. Murayama A, Hoshi M, Saito H, Kamamoto S, Tanaka M, Kawashima M, et
al. Nature and Trends in Personal Payments Made to the Respiratory
Physicians by Pharmaceutical Companies in Japan between 2016 and 2019.
Respiration. 2022;101(12):1088-98.
18. Kusumi E, Murayama A, Kamamoto S, Kawashima M, Yoshida M, Saito H,
et al. Pharmaceutical payments to Japanese certified hematologists: a
retrospective analysis of personal payments from pharmaceutical
companies between 2016 and 2019. Blood Cancer J. 2022;12(4):54.
19. Kamamoto S, Murayama A, Kusumi E, Yoshida M, Saito H, Sawano T, et
al. Evaluation of financial relationships between Japanese certified
pediatric hematologist/oncologists and pharmaceutical companies: a
cross-sectional analysis of personal payments from pharmaceutical
companies between 2016 and 2019. Pediatr Blood Cancer.
2022;69(10):e29891.
20. Murayama A, Saito H, Kamamoto S, Shigeta H, Yamashita E, Tanimoto T,
Ozaki A. Evaluation of non-research payments from pharmaceutical
companies to urologists in Japan between 2016 and 2019. Int Urogynecol
J. 2023;34(6):1285-92.
21. Murayama A, Mamada H, Shigeta H, Yoshinaga T, Saito H, Yamashita E,
et al. Financial Relationships Between Pharmaceutical Companies and
Rheumatologists in Japan Between 2016 and 2019. J Clin Rheumatol.
2023;29(3):118-25.
22. Murayama A, Kamamoto S, Saito H, Ozaki A. Pharmaceutical payments to
Japanese board-certified dermatologists: a 4-year retrospective analysis
of personal payments from pharmaceutical companies between 2016 and
2019. Sci Rep. 2023;13(1):7425.
23. Murayama A, Kamamoto S, Kawashima M, Saito H, Yamashita E, Tanimoto
T, Ozaki A. Cross-sectional analysis of pharmaceutical payments to
Japanese board-certified gastroenterologists between 2016 and 2019. BMJ
Open. 2023;13(4):e068237.
24. Murayama A. Financial Conflicts of Interest Among the Authors of the
Clinical Practice Guidelines for Rheumatoid Arthritis in Japan. Cureus.
2023;15(10):e46650.
25. Murayama A, Saito H, Tanimoto T, Ozaki A. Financial conflicts of
interest between pharmaceutical companies and executive board members of
internal medicine subspecialty societies in Japan between 2016 and 2020.
J Eval Clin Pract. 2023;29(6):883-6.
26. Murayama A, Kamamoto S, Murata N, Yamasaki R, Yamada K, Yamashita E,
et al. Evaluation of financial conflicts of interest and quality of
evidence in Japanese gastroenterology clinical practice guidelines. J
Gastroenterol Hepatol. 2023;38(4):565-73.
27. Mamada H, Murayama A, Kamamoto S, Kaneda Y, Yoshida M, Sugiura S, et
al. Evaluation of Financial and Nonfinancial Conflicts of Interest and
Quality of Evidence Underlying Psoriatic Arthritis Clinical Practice
Guidelines: Analysis of Personal Payments From Pharmaceutical Companies
and Authors’ Self-Citation Rate in Japan and the United States.
Arthritis Care Res (Hoboken). 2023;75(6):1278-86.
28. Murayama A, Kamamoto S, Shigeta H, Saito H, Yamashita E, Tanimoto T,
Akihiko O. Undisclosed financial conflicts of interest with
pharmaceutical companies among the authors of the Esophageal Cancer
Practice Guidelines 2017 by the Japan Esophageal Society. Dis Esophagus.
2022;35(10).
29. Yamamoto K, Murayama A, Ozaki A, Saito H, Sawano T, Tanimoto T.
Financial conflicts of interest between pharmaceutical companies and the
authors of urology clinical practice guidelines in Japan. Int Urogynecol
J. 2021;32(2):443-51.
30. Hashimoto T, Murayama A, Mamada H, Saito H, Tanimoto T, Ozaki A.
Evaluation of financial conflicts of interest and drug statements in the
coronavirus disease 2019 clinical practice guideline in Japan. Clin
Microbiol Infect. 2022;28(3):460-2.
31. Harada K, Ozaki A, Saito H, Sawano T, Yamamoto K, Murayama A, et al.
Financial payments made by pharmaceutical companies to the authors of
Japanese hematology clinical practice guidelines between 2016 and 2017.
Health Policy. 2021;125(3):320-6.
32. Kida F, Murayama A, Saito H, Ozaki A, Shimada Y, Tanimoto T.
Pharmaceutical company payments to authors of the Japanese Clinical
Practice Guidelines for Hepatitis C treatment. Liver Int.
2021;41(3):464-9.
33. Murayama A. Nine-Year Analysis of Industry Payments to Geriatricians
in the United States Between 2014 and 2022. J Am Med Dir Assoc. 2023.
34. Murayama A, Kamamoto S, Higuchi K, Shigeta H, Ozaki A. Trend in
Industry Payments to Rheumatologists in the United States During the
COVID-19 Pandemic Between 2013 and 2021. J Rheumatol. 2023;50(4):575-7.
35. Murayama A, Kamamoto S, Kugo H, Saito H, Ozaki A. Research and
Nonresearch Industry Payments to Nephrologists in the United States
between 2014 and 2021. J Am Soc Nephrol. 2023;34(10):1709-20.
36. Murayama A, Kamamoto S, Shigeta H, Ozaki A. Industry Payments During
the COVID-19 Pandemic to Cardiologists in the United States. CJC Open.
2023;5(3):253-5.
37. Murayama A, Kugo H, Saito Y, Saito H, Tanimoto T, Ozaki A. A 9-Year
Investigation of Healthcare Industry Payments to Pulmonologists in the
United States. Ann Am Thorac Soc. 2023;20(9):1283-92.
38. Murayama A. A nine-year investigation of industry research and
non-research payments to emergency physicians in the United States
between 2014 and 2022. The Journal of Emergency Medicine. 2023.
39. Murayama A. Evaluation of Research and Non-research Industry
Payments to Endocrinologists in the United States: An Analysis of the
Open Payments Database from 2014 to 2022. Diabet Med. 2023:e15253.
40. Murayama A, Nakano K, Kamamoto S, Sato M, Saito H, Tanimoto T, Ozaki
A. Trend in industry payments to infectious disease physicians in the
United States: a seven-year analysis of nonresearch payments from the
Open Payments Database between 2014 and 2020. Clin Microbiol Infect.
2022;28(12):1655 e1- e4.
41. Murayama A, Kamamoto S, Saito H, Tanimoto T, Ozaki A. Industry
payments to allergists and clinical immunologists in the United States
during the coronavirus disease 2019 pandemic. Ann Allergy Asthma
Immunol. 2022;129(5):635-6.
42. Ying X, Rosenblatt R, Fortune BE. Trends in Industry Payments to
Gastroenterologists and Hepatologists in the United States From 2014 to
2020. Gastroenterology. 2022;163(4):787-91.
43. Marshall DC, Tarras ES, Rosenzweig K, Korenstein D, Chimonas S.
Trends in Industry Payments to Physicians in the United States From 2014
to 2018. JAMA. 2020;324(17):1785-8.
44. Murayama A, Hirota S. Industry payments to pathologists in the USA
between 2013 and 2021. J Clin Pathol. 2023;76(8):566-70.
45. Karanges EA, Ting N, Parker L, Fabbri A, Bero L. Pharmaceutical
industry payments to leaders of professional medical associations in
Australia: Focus on cardiovascular disease and diabetes. Aust J Gen
Pract. 2020;49(3):151-4.
46. Pokorny AMJ, Bero LA, Moynihan R, Mintzes BJ. Industry payments to
Australian medical oncologists and clinical haematologists: a
cross-sectional analysis of publicly available disclosures. Intern Med
J. 2021;51(11):1816-24.
47. Clinckemaillie M, Scanff A, Naudet F, Barbaroux A. Sunshine on KOLs:
assessment of the nature, extent and evolution of financial ties between
the leaders of professional medical associations and the pharmaceutical
industry in France from 2014 to 2019: a retrospective study. BMJ Open.
2022;12(2):e051042.
48. Ikeda S, Mimura M, Ikeda M, Wada-Isoe K, Azuma M, Inoue S, Tomita K.
Economic Burden of Alzheimer’s Disease Dementia in Japan. J Alzheimers
Dis. 2021;81(1):309-19.
49. Nakahori N, Sekine M, Yamada M, Tatsuse T, Kido H, Suzuki M. Future
projections of the prevalence of dementia in Japan: results from the
Toyama Dementia Survey. BMC Geriatrics. 2021;21(1):602.
50. Japanese Society of Allergology. List of board-certified allergy
specialists and advisors Online: Japanese Society of Allergology; 2022
[Available from:https://www.jsaweb.jp/modules/specialist/index.php?content_id=6.
51. Japan Pharmaceutical Manufacturers Association. Regarding the
Transparency Guideline for the Relation between Corporate Activities and
Medical Institutions 2018 [Available from:https://www.jpma.or.jp/english/code/transparency_guideline/eki4g60000003klk-att/transparency_gl_intro_2018.pdf.
52. Medical Governance Research Institute, Tansa. Yen For Docs [Online
database]. Medical Governance Research Institute; 2023 [updated
September 11, 2023. Available from:https://yenfordocs.jp/.
53. Subramanian S. An Elementary Interpretation of the Gini Inequality
Index. Theory and Decision. 2002;52(4):375-9.
54. Inoue K, Figueroa JF, Kondo N, Tsugawa Y. Changes in industry
marketing payments to physicians during the covid-19 pandemic: quasi
experimental, difference-in-difference study. BMJ Medicine.
2022;1(1):e000219.
55. Marcum ZA, Chang CY, Barthold D, Holmes HM, Lo-Ciganic WH. Industry
Payments to Physicians and Prescribing Branded Memantine and Donepezil
Combination. Neurol Clin Pract. 2021;11(3):181-7.
Table 1. Summary of personal payments to board-certified neurologists